Cervical Cancer Deaths Fall to Zero Among Young Women in England Following HPV Vaccine Rollout

For the first time in recorded medical history, a demographic cohort in England has experienced exactly zero deaths from cervical cancer over a five-year period.[1][2]

Between 2020 and 2024, not a single woman aged 20 to 24 in England died from the disease, according to a landmark study published in The Lancet.[4]

The milestone is the direct result of the national human papillomavirus (HPV) vaccination program introduced in 2008, providing definitive proof that a prophylactic vaccine can effectively eliminate a specific cancer.[1][8]

"It's incredible to think that a single jab can almost eliminate a particular type of cancer," noted Professor Peter Sasieni, the lead researcher of the study from Queen Mary University of London.[1][4]

Cervical cancer is the fourth most common cancer in women globally, and high-risk strains of HPV are responsible for 99% of all cases.[2][5]

HPV is a common virus transmitted through close skin-to-skin contact; while most infections clear naturally, persistent infections can cause abnormal cellular changes in the cervix that slowly develop into invasive cancer over years or decades.[2][6]

The Lancet study, funded by Cancer Research UK, analyzed official cancer mortality and vaccination data for women aged 20 to 34 to calculate the real-world impact of the national immunization effort.[2][4]

Researchers found that women who received the HPV vaccine in early adolescence, typically at age 12 or 13, now face an almost zero risk of dying from cervical cancer before the age of 30.[2][3]

Before the national vaccination program began, approximately 20 women under the age of 30 died from the disease in England each year.[1]

The data reveals a steep, progressive decline: from 2015 to 2019, there was an 80% reduction in cervical cancer deaths among women aged 20 to 24, paving the way for the zero-death period that followed.[3][4]

For slightly older vaccinated cohorts, the benefits remain profound; women aged 30 to 34 who received the vaccine experienced a 63% lower relative risk of death from the disease compared to unvaccinated peers.[2][4]

In total, epidemiologists estimate that the HPV vaccination program has already prevented nearly 200 young women from dying of cervical cancer in England alone.[2][3]

Because cervical cancer typically takes years to develop, researchers expect the number of lives saved to compound exponentially as the vaccinated generations grow older and enter the age brackets where the disease historically peaks.[3][6]

However, public health officials are warning that this hard-won progress is increasingly fragile due to a post-pandemic slump in immunization rates.[2][6]

Data from the UK Health Security Agency indicates that national HPV vaccine uptake has fallen to approximately 75%, and sits as low as 60% in parts of London—well below the 90% threshold recommended by the World Health Organization.[2][5][7]

If uptake does not return to pre-pandemic levels, epidemiological models suggest the UK could see a reversal of these trends, potentially resulting in 15 to 25 avoidable deaths each year among young women.[2][4]

The success in England also highlights a stark global inequity; according to the World Health Organization, nearly 94% of the 350,000 global cervical cancer deaths in 2022 occurred in low- and middle-income countries where vaccine access remains severely limited.[5]

To address this, the WHO's Cervical Cancer Elimination Initiative has set a global target to fully vaccinate 90% of girls by the age of 15, alongside scaling up screening and treatment infrastructure.[5]

For now, the English data serves as an unprecedented proof of concept for the global medical community.[8]

It demonstrates unequivocally that with sustained public health interventions, cervical cancer can be transformed from a leading cause of mortality into a preventable, rare disease.[4][6]